サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753064

群発頭痛の世界市場

Cluster Headache

出版日
ページ情報
英文 471 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.72円
群発頭痛の世界市場
出版日: 2025年06月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 471 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

群発頭痛の世界市場は2030年までに5億6,040万米ドルに達する見込み

2024年に4億970万米ドルと推定される群発頭痛の世界市場は、2024年から2030年にかけてCAGR 5.4%で成長し、2030年には5億6,040万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるEpisodicは、CAGR 6.3%を記録し、分析期間終了時には3億7,970万米ドルに達すると予測されます。慢性セグメントの成長率は、分析期間中CAGR 3.6%と推定されます。

米国市場は1億1,160万米ドルと推定、中国はCAGR 8.7％で成長予測

米国の群発頭痛市場は、2024年に1億1,160万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億1,330万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.4％と予測されています。欧州では、ドイツがCAGR 3.5%で成長すると予測されています。

世界の群発頭痛市場- 主要動向と促進要因のまとめ

群発頭痛管理が神経学、慢性疼痛治療、QOL介入で重要性を増す理由とは？

群発頭痛は、その激しさからしばしば「自殺頭痛」と呼ばれ、生活の質や生産性を著しく損なう衰弱性神経疾患として、医学的・研究的に注目を集めています。群発頭痛は、片側の激しい痛み、典型的には眼の周囲の痛み、周期的なパターンで起こることが特徴で、最も耐え難い一次性頭痛疾患のひとつです。片頭痛と比較すると比較的まれではあるが、群発頭痛の慢性的または反復的な性質と普遍的に有効な治療法の欠如により、より専門的な診断および治療アプローチが求められています。

臨床医や患者の間で認知度が高まるにつれ、群発頭痛市場は、効果的で即効性のある緩和策、長期的な管理オプション、神経科医主導のケアへの幅広いアクセスに対する緊急のニーズによって形成されつつあります。特に、他の頭痛タイプとの誤診がタイムリーな治療を阻む一般的な障壁となっているためです。

群発頭痛治療は、治療方法、治療メカニズム、患者中心のアプローチによってどのように進歩しているのか？

群発頭痛の現在の管理戦略は、急性期の緩和、再発予防、発作頻度の減少に重点を置いています。急性エピソードに対する第一選択治療は、高流量酸素療法と、発作を速やかに中止するための即効性トリプタン系薬剤（特に皮下または点鼻薬）です。予防療法としては、副腎皮質ステロイド、リチウム、難治例ではCGRP標的生物学的製剤と並んで、ベラパミルが依然として一般的に処方されています。

自動注射器や点鼻薬などのドラッグデリバリーの進歩により、群発エピソードの急速な発症に対処する上で重要な要素である、投与の速度と簡便性が改善されつつあります。神経調節療法（非侵襲的迷走神経刺激など）やモノクローナル抗体の研究も進められており、群発頭痛を含め、より広範な頭痛スペクトラム管理のために設計されています。

これと並行して、頭痛追跡アプリや遠隔神経学的診察などのデジタルヘルスツールが、患者の関与と症状モニタリングをサポートし、より個別化された治療レジメンを可能にし、治療調整までの時間を短縮しています。薬剤開発者は、短周期のエピソード性群発頭痛と長期の慢性型群発頭痛の両方を対象としているため、臨床試験活動は活発化しています。

群発頭痛治療の普及に影響を与えているヘルスケア環境と地域動向は？

群発頭痛患者は通常、神経内科クリニック、頭痛専門センター、三次医療病院で管理されており、そこでは画像診断や鑑別診断のプロトコルが二次的な頭痛の原因を除外するのに役立っています。一般開業医や救急部門も、特に診断が不十分な地域では、急性期治療や紹介経路において役割を果たしています。

北米と欧州は、診断率が高いこと、専門医による治療が受けられること、新しい薬理学的治療や非薬理学的治療が受けられることから、最大の市場となっています。アジア太平洋はまだ新興市場であるが、特に神経学のインフラが整備されつつある都市部で認知度が高まっています。ラテンアメリカ、中東・アフリカでは、診断と治療はまだ限定的であるが、公衆衛生教育とアドボカシー活動により、疾患の認知度は徐々に向上しています。

群発頭痛市場の成長を促す要因とは？

群発頭痛治療薬の市場は、臨床的認知が向上し、迅速な症状緩和や長期管理に対するアンメットニーズが依然として高いことから、拡大しています。本疾患は衰弱しやすく、慢性的あるいは再発を繰り返すため、患者にとっても、神経学的QOLを重視するヘルスケアシステムにとっても、効果的な治療が優先課題となっています。

主な成長促進要因としては、頭痛に特化した薬剤製剤の進歩、神経内科サービスの拡大、臨床試験活動の活発化、非侵襲的治療オプションに対する需要の高まりなどが挙げられます。患者擁護、頭痛の病態生理学の理解拡大、デジタルヘルスプラットフォームの導入も、早期介入と持続的治療に貢献しています。

神経疾患の負担が世界的に増大する中、群発頭痛療法は、個別化された精密ガイドによる疼痛管理戦略の新たなフロンティアとなり得るだろうか。

セグメント

タイプ（episodic、chronic）;薬剤タイプ（即効薬、長期投与薬、短期投与薬）;投与経路（経口、局所、静脈内、その他の投与経路）;販売チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全42件）

  • AbbVie Inc.
  • Allergan（a subsidiary of AbbVie）
  • Amgen Inc.
  • AstraZeneca
  • Bausch Health Companies Inc.
  • BetterLife Pharma Inc.
  • Ceruvia Lifesciences
  • Clexio Biosciences
  • Dr. Reddy's Laboratories Ltd.
  • ElectroCore, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lundbeck Seattle BioPharmaceuticals
  • Lupin Limited
  • Novartis AG
  • Perrigo Company plc
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34811

Global Cluster Headache Market to Reach US$560.4 Million by 2030

The global market for Cluster Headache estimated at US$409.7 Million in the year 2024, is expected to reach US$560.4 Million by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Episodic, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$379.7 Million by the end of the analysis period. Growth in the Chronic segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$111.6 Million While China is Forecast to Grow at 8.7% CAGR

The Cluster Headache market in the U.S. is estimated at US$111.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$113.3 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Cluster Headache Market - Key Trends & Drivers Summarized

Why Is Cluster Headache Management Gaining Importance in Neurology, Chronic Pain Therapy, and Quality of Life Interventions?

Cluster headache-often termed “suicide headache” due to its extreme intensity-is gaining medical and research attention as a debilitating neurological disorder that significantly impairs quality of life and productivity. Characterized by severe unilateral pain, typically around the eye, and occurring in cyclical patterns, cluster headaches are among the most excruciating primary headache disorders. Though relatively rare compared to migraine, the chronic or episodic nature of cluster headaches and the lack of universally effective treatments are driving demand for more specialized diagnostic and therapeutic approaches.

As awareness grows among clinicians and patients alike, the cluster headache market is being shaped by an urgent need for effective, fast-acting relief, long-term management options, and broader access to neurologist-guided care. Improved recognition of the condition is leading to earlier diagnosis and targeted intervention, particularly as misdiagnosis with other headache types remains a common barrier to timely treatment.

How Are Therapeutic Modalities, Delivery Mechanisms, and Patient-Centric Approaches Advancing Cluster Headache Treatment?

Current management strategies for cluster headache focus on acute relief, prevention of recurrence, and reduction of attack frequency. First-line treatments for acute episodes include high-flow oxygen therapy and fast-acting triptans (particularly subcutaneous or nasal formulations) to abort attacks quickly. For preventive therapy, verapamil remains a commonly prescribed agent, alongside corticosteroids, lithium, and CGRP-targeting biologics in refractory cases.

Advances in drug delivery mechanisms-such as auto-injectors and intranasal sprays-are improving speed and ease of administration, critical factors in managing the rapid onset of cluster episodes. Research is also underway into neuromodulation therapies (e.g., non-invasive vagus nerve stimulation) and monoclonal antibodies designed for broader headache spectrum management, including cluster headache.

In parallel, digital health tools such as headache tracking apps and remote neurology consultations are supporting patient engagement and symptom monitoring, enabling more personalized treatment regimens and reducing time to therapeutic adjustment. Clinical trial activity is increasing as drug developers target both short-cycle episodic cluster headaches and long-term chronic forms.

Which Healthcare Settings and Regional Trends Are Influencing Cluster Headache Treatment Uptake?

Cluster headache patients are typically managed in neurology clinics, headache specialty centers, and tertiary care hospitals where imaging and differential diagnosis protocols help rule out secondary headache causes. General practitioners and emergency departments also play a role in acute care and referral pathways, particularly in underdiagnosed regions.

North America and Europe represent the largest markets due to higher diagnosis rates, availability of specialist care, and access to newer pharmacologic and non-pharmacologic treatments. Asia-Pacific, while still emerging, is witnessing increased awareness, particularly in urban centers with growing neurology infrastructure. In Latin America, the Middle East, and Africa, diagnosis and treatment remain limited, but public health education and advocacy efforts are gradually improving condition recognition.

What Are the Factors Driving Growth in the Cluster Headache Market?

The market for cluster headache therapeutics is growing as clinical awareness improves and unmet needs in rapid symptom relief and long-term management remain high. The debilitating nature of the disorder, combined with its chronic or recurrent episodes, makes effective treatment a priority for both patients and healthcare systems focused on neurological quality of life.

Key growth drivers include advancements in headache-specific drug formulations, expansion of neurology services, increased clinical trial activity, and rising demand for non-invasive treatment options. Patient advocacy, greater understanding of headache pathophysiology, and the introduction of digital health platforms are also contributing to early intervention and sustained care.

As the burden of neurological disorders escalates globally, could cluster headache therapies become a new frontier in personalized, precision-guided pain management strategies?

SCOPE OF STUDY:

The report analyzes the Cluster Headache market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Episodic, Chronic); Drug Type (Fast-Acting Drugs, Long-Term Drugs, Short-Term Drugs); Administration Route (Oral, Topical, Intravenous, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Allergan (a subsidiary of AbbVie)
  • Amgen Inc.
  • AstraZeneca
  • Bausch Health Companies Inc.
  • BetterLife Pharma Inc.
  • Ceruvia Lifesciences
  • Clexio Biosciences
  • Dr. Reddy's Laboratories Ltd.
  • ElectroCore, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lundbeck Seattle BioPharmaceuticals
  • Lupin Limited
  • Novartis AG
  • Perrigo Company plc
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Cluster Headache - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Diagnosis of Trigeminal Autonomic Cephalalgias Throws the Spotlight on Cluster Headache Management
    • Growth in Awareness of Chronic and Episodic Cluster Headaches Spurs Demand for Acute and Preventive Therapies
    • Development of Targeted Treatments Including CGRP Antagonists and Sphenopalatine Ganglion Blocks Enhances Relief Options
    • Expansion of Portable Oxygen Therapy Devices and Neuromodulation Tools Supports Home-Based Symptom Control
    • Use of Lithium, Verapamil, and Galcanezumab in Off-Label and On-Label Protocols Broadens Clinical Management Approaches
    • Integration With Digital Headache Diaries and Wearables Supports Trigger Monitoring and Pattern Analysis
    • Growth in Dedicated Headache Clinics and Neurology Teleconsultations Improves Timely Access to Care
    • Focus on Early Intervention During Cluster Periods Enhances Patient Quality of Life and Work Functionality
    • Patient Advocacy and Awareness Campaigns Promote Faster Diagnosis and Insurance Coverage for Treatment
    • Recognition of Cluster Headache as a Neurological Disability Supports Policy and Research Funding
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cluster Headache Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cluster Headache by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Episodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Episodic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Episodic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Fast-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Fast-Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Fast-Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Long-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Long-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Long-Term Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Short-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Short-Term Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Short-Term Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Cluster Headache by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 140: UK Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Cluster Headache by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 215: India Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Cluster Headache by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Cluster Headache by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Cluster Headache by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Cluster Headache Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Cluster Headache by Type - Episodic and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Cluster Headache by Type - Episodic and Chronic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Cluster Headache by Type - Percentage Breakdown of Value Sales for Episodic and Chronic for the Years 2015, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Cluster Headache by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Cluster Headache by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Cluster Headache by Drug Type - Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Cluster Headache by Drug Type - Percentage Breakdown of Value Sales for Fast-Acting Drugs, Long-Term Drugs and Short-Term Drugs for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Cluster Headache by Administration Route - Oral, Topical, Intravenous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Cluster Headache by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical, Intravenous and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION